900233624 09/17/2012

TRADEMARK ASSIGNMENT

Electronic Version v1.1 Stylesheet Version v1.1

| SUBMISSION TYPE: | NEW ASSIGNMENT |
|-----------------------|--|
| NATURE OF CONVEYANCE: | ASSIGNS THE ENTIRE INTEREST AND THE GOODWILL |

CONVEYING PARTY DATA

| Name | Formerly | Execution Date | Entity Type |
|----------------------------|----------|----------------|-----------------------|
| Revance Therapeutics, Inc. | | 08/05/2011 | CORPORATION: DELAWARE |

RECEIVING PARTY DATA

| Name: | Precision Dermatology, Inc. | |
|-----------------|---|--|
| Street Address: | 900 Highland Corporate Drive, Suite 203 | |
| City: | Cumberland | |
| State/Country: | RHODE ISLAND | |
| Postal Code: | 02864 | |
| Entity Type: | CORPORATION: DELAWARE | |

PROPERTY NUMBERS Total: 3

| Property Type | Number | Word Mark |
|----------------------|----------|-----------|
| Registration Number: | 3750739 | RELASTIN |
| Serial Number: | 85023244 | RELASTIN |
| Registration Number: | 3453187 | EYE SILK |

CORRESPONDENCE DATA

Fax Number: 6178327000

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

via US Mail.

Phone: 617.832.1000

Email: ustrademark@foleyhoag.com

Correspondent Name: Charles Weinstein, Esq., Foley Hoag LLP

Address Line 1: 155 Seaport Boulevard

Address Line 4: Boston, MASSACHUSETTS 02210

| ATTORNEY DOCKET NUMBER: | 30071.00003 |
|-------------------------|--|
| NAME OF SUBMITTER: | Linda Casey, Paralegal, Foley Hoag LLP |

TRADEMARK REEL: 004862 FRAME: 0304

900233624

| Signature: | /Linda Casey/ |
|--|---------------|
| Date: | 09/17/2012 |
| Total Attachments: 4 source=Revance Trademark Assignment FULLY EXECUTED#page1.tif source=Revance Trademark Assignment FULLY EXECUTED#page2.tif source=Revance Trademark Assignment FULLY EXECUTED#page3.tif source=Revance Trademark Assignment FULLY EXECUTED#page4.tif | |

TRADEMARK
REEL: 004862 FRAME: 0305

TRADEMARK ASSIGNMENT

WHEREAS, Revance Therapeutics, Inc., a corporation duly organized under the laws of the State of Delaware ("Assignor"), owns all right, title, and interest in the trademarks and trademark applications set forth on Schedule 1 attached hereto and made a part hereof (collectively, the "Trademarks") as shown in the records in the United States Patent and Trademark Office; and

WHEREAS, Precision Dermatology, Inc., a corporation duly organized under the laws of the State of Delaware ("Assignee"), desires to own Assignor's entire right, title, and interest in and to the Trademarks.

NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Assignor hereby sells, assigns, and transfers unto Assignee the entire right, title and interest in and to the Trademarks together with the good will of the business connected therewith and symbolized thereby and all accrued causes of action for damages for infringement thereof, the same to be held and enjoyed by Assignee for its own use and benefits, and for its legal representatives and assigns, as fully and as entirely as the same would have been held by Assignor had this assignment and sale not been made. Notwithstanding anything to the contrary, nothing herein shall expand or modify the rights or obligations of the parties as set forth in that certain Asset Purchase Agreement dated as of August 5, 2011 by and between Assignor and Assignee, as amended.

This Trademark Assignment shall be binding upon and shall inure solely to the benefit of Assignor and Assignee and their respective successors and assigns.

This Trademark Assignment shall be governed by and construed in accordance with the internal laws of the State of California, without regard to any applicable principles of conflicts of law.

[signature page follows]

UBC/4110761.15 TRADE

SCHEDULE 1

Trademarks

1) RELASTIN

U.S. Reg. No. 3750739 for "Eye gels and creams, face creams and lotions and body creams and lotions for cosmetic uses" in Class 3 and "Eye gels and creams, face creams and lotions and body creams and lotions for medical uses" in Class 5, issued February 16, 2010, based on use in commerce since August 28, 2006.

U.S. App. No. 85023244 for "Cosmetics" in Class 3, filed based on intent-to-use on April 26, 2010, allowed on November 23, 2010, statement of use based on use in commerce since August 28, 2006 filed May 23, 2011 and accepted June 24, 2011.

2) EYE SILK

U.S. Reg. No. 3453187 for "Eye creams used as cosmetic preparations for skin renewal, skin firming and skin wrinkle removing" in Class 3, issued June 24, 2008, based on use as of July 6, 2007.

3) ZINC FIRMING COMPLEX

Common law (unregistered) mark in use in the United States since August 28, 2006.

- 4) www.relastin.com
- 5) Trade Dress and Logos as shown on relastin.com:



Common law (unregistered) trademarks in the foregoing in use in the United States since August 28, 2006.

TRADEMARK
REEL: 004862 FRAME: 0307

IN WITNESS WHEREOF, Assignor has caused this Trademark Assignment to be executed by its duly authorized officer on August 5, 2011.

REVANCE THERAPEUTICS, INC.

By:

COUNTY OF

On this 5th day of August, 2011 personally appeared <u>Rowel</u> to me personally known, who, being by me duly sworn, did depose and say that he is the President + CEO of Revance Therapeutics, Inc., the corporation described in and which executed the foregoing instrument and that he did sign said instrument as such officer and on behalf of such corporation.

LINDA KAYE ALLES COMM. #1901551 Notary Public - California San Mateo County

IN WITNESS WHEREOF, the undersigned has executed this Secretary's Certificate on behalf of the Company as of the date first set above.

REVANCE THERAPEUTICS, INC.

By: ____ Name:

Title:

Secretary

I, David Styka, do hereby certify that I am the duly elected and acting Chief Financial Officer of the Company, and that as of the date hereof, CPAIS The duly elected and acting Secretary of the Company.

REVANCE THERAPEUTICS, INC.

Name: David Styka

Title: Chief Financial Officer

[SIGNATURE PAGE TO SECRETARY'S CERTIFICATE OF REVANCE THERAPEUTICS, INC.]

TRADEMARK REEL: 004862 FRAME: 0309

RECORDED: 09/17/2012